News Focus
News Focus
icon url

rick25

01/09/26 8:01 AM

#444305 RE: TCI1 #444303

This PR is about payer positioning, not chasing generics. Emphasizing sHTG/MARINE highlights VASCEPA as the logical first-line step before higher-cost injectables. Proven data still matters.
icon url

rosemountbomber

01/09/26 8:20 AM

#444308 RE: TCI1 #444303

That press release costs them nothing.